San Francisco Sentry Investment Group CA grew its holdings in shares of Novartis AG (NYSE:NVS) by 15.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,904 shares of the company’s stock after purchasing an additional 904 shares during the period. San Francisco Sentry Investment Group CA’s holdings in Novartis were worth $593,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of NVS. Geode Capital Management LLC increased its holdings in shares of Novartis by 19.8% during the first quarter. Geode Capital Management LLC now owns 18,918 shares of the company’s stock valued at $1,405,000 after purchasing an additional 3,125 shares during the period. Bank of Montreal Can grew its holdings in Novartis by 5.4% during the second quarter. Bank of Montreal Can now owns 169,362 shares of the company’s stock worth $14,136,000 after acquiring an additional 8,714 shares during the period. Narwhal Capital Management grew its holdings in Novartis by 4.1% during the second quarter. Narwhal Capital Management now owns 49,960 shares of the company’s stock worth $4,170,000 after acquiring an additional 1,950 shares during the period. Pennsylvania Trust Co grew its holdings in Novartis by 25.3% during the second quarter. Pennsylvania Trust Co now owns 83,362 shares of the company’s stock worth $6,958,000 after acquiring an additional 16,816 shares during the period. Finally, Union Bankshares Corp grew its holdings in Novartis by 0.3% during the second quarter. Union Bankshares Corp now owns 37,521 shares of the company’s stock worth $3,132,000 after acquiring an additional 99 shares during the period. 10.87% of the stock is currently owned by institutional investors.

A number of research analysts recently issued reports on the company. BidaskClub lowered Novartis from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Cowen set a $90.00 target price on Novartis and gave the stock a “hold” rating in a report on Wednesday, August 9th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis in a report on Tuesday, September 26th. Barclays lowered Novartis from an “equal weight” rating to an “underweight” rating in a report on Wednesday, October 25th. Finally, Leerink Swann lifted their target price on Novartis from $89.00 to $91.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and four have given a buy rating to the company’s stock. Novartis currently has an average rating of “Hold” and an average target price of $85.32.

Novartis AG (NYSE NVS) opened at $86.05 on Friday. The firm has a market capitalization of $203,559.45, a PE ratio of 18.12, a P/E/G ratio of 2.75 and a beta of 0.73. Novartis AG has a 12 month low of $66.93 and a 12 month high of $86.90. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.08 and a quick ratio of 0.81.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.25 by $0.04. The firm had revenue of $12.41 billion for the quarter, compared to analysts’ expectations of $12.21 billion. Novartis had a return on equity of 15.77% and a net margin of 13.73%. Novartis’s revenue was up 2.4% on a year-over-year basis. During the same quarter last year, the business posted $1.23 EPS. analysts expect that Novartis AG will post 4.75 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.watchlistnews.com/novartis-ag-nvs-shares-bought-by-san-francisco-sentry-investment-group-ca/1741311.html.

Novartis Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.